You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,790,475


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,790,475
Title:Apparatuses and methods for reducing albumin in samples
Abstract: The present invention is directed to apparatuses and methods for reducing the content of albumin in serum, plasma and/or blood samples. The apparatuses comprise an insoluble support with a ligand attached thereto. According to certain embodiments of the invention, the ligand is a bromosulfophthalein, Cibacron Blue or Warfarin ligand or salts or esters thereof. Also provided are methods of making the apparatus, as well as kits and albumin-depleted samples produced by the methods of the present invention.
Inventor(s): Galbraith; William (Paxton, MA)
Assignee: Becton, Dickinson and Company (Franklin Lakes, NJ)
Application Number:10/922,560
Patent Claims:1. A method for producing an albumin-depleted sample, comprising: providing a sample, which sample includes albumin and phosphate-buffered saline; running the sample over an insoluble support having attached thereto a ligand comprising at least one hydroxyl group, said ligand consisting of bromosulfophthalein or a salt or ester thereof, said ligand attached to said insoluble support via an epoxy linkage; and allowing albumin from the sample to bind to the ligand, thereby providing the albumin-depleted sample.

2. The method of claim 1, further comprising collecting the albumin-depleted sample.

3. The method of claim 1, further comprising: running the albumin-depleted sample over the insoluble support one or more additional times; and allowing albumin from the albumin-depleted sample to bind to the ligand, thereby providing a further albumin-depleted sample.

4. The method of claim 3, further comprising collecting the further albumin-depleted sample.

5. The method of claim 1, wherein the sample is selected from the group consisting of serum, plasma, and blood.

6. The method of claim 1, wherein the albumin is human serum albumin.

7. A method for producing a protein-depleted sample, comprising: providing a sample, which sample includes albumin and one or more additional proteins and phosphate-buffered saline; running the sample over an insoluble support having a ligand comprising at least one hydroxyl group, said ligand consisting of bromosulfophthalein or a salt or ester thereof, said ligand attached to said insoluble support via an epoxy linkage, allowing albumin from the sample to bind to the ligand; running the sample over one or more insoluble supports adapted to be capable of preferentially removing one or more non-albumin proteins from the sample; and allowing the one or more non-albumin proteins to be removed from the sample, thereby providing a protein-depleted sample.

8. The method of claim 7, further comprising collecting the protein-depleted sample.

9. The method of claim 7, further comprising: running the protein-depleted sample over one or more of the insoluble supports one or more additional times; and allowing additional proteins from the protein-depleted sample to be removed, thereby providing a further protein-depleted sample.

10. The method of claim 7, wherein the steps of running the sample over one or more other insoluble supports adapted to be capable of preferentially removing one or more non-albumin proteins from the sample and allowing the one or more non-albumin proteins to be removed from the sample are performed before running the sample over an insoluble support having a ligand capable of preferentially binding albumin and allowing albumin from the sample to bind to the ligand.

11. The method of claim 7, wherein the albumin is human serum albumin.

12. The method of claim 5, wherein said serum is present in a concentration of a 1:2 ratio of serum to phosphate-buffered saline.

13. The method of claim 7, wherein the sample is selected from the group consisting of serum, plasma, and blood.

14. The method of claim 13, wherein said serum is present in a concentration of a 1:2 ratio of serum to phosphate-buffered saline.

Details for Patent 7,790,475

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Grifols Therapeutics Llc ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 albumin (human) For Injection 101138 10/21/1942 ⤷  Try a Trial 2023-09-25
Baxalta Us Inc. BUMINATE, FLEXBUMIN albumin (human) Injection 101452 03/03/1954 ⤷  Try a Trial 2023-09-25
Csl Behring Ag ALBURX albumin (human) Injection 102366 07/23/1976 ⤷  Try a Trial 2023-09-25
Grifols Biologicals Llc ALBUTEIN albumin (human) Injection 102478 08/15/1978 ⤷  Try a Trial 2023-09-25
Instituto Grifols, S.a. HUMAN ALBUMIN GRIFOLS albumin (human) Injection 103352 02/17/1995 ⤷  Try a Trial 2023-09-25
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.